hPV 19

Drug Profile

hPV 19

Alternative Names: hPV 19K; hPV19

Latest Information Update: 18 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stainwei Biotech
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Vascular endothelial growth factors inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Eye disorders

Most Recent Events

  • 03 May 2017 Phase-I clinical trials in Solid tumours in China (Parenteral)
  • 03 May 2017 Preclinical trials in Eye disorders in China (unspecified route)
  • 03 May 2017 Stainwei Biotech has patent protection for hPV 19 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top